OSCR
Oscar Health, Inc.
OSCR's outlook is improving, though it still trails on the overall score.
SKHY
SK hynix Inc.
SKHY has the edge over OSCR overall, supported by stronger fundamentals.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SKHY Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
SKHY's revenue, profitability, cash flow and balance sheet are all currently strong.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SKHY PE Valuation
SKHY has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SKHY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for SKHY, with profitability improving. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
SKHY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $17.04 | +461% |
| Q1 2026 | $7.91 | +187% |
| Q4 2025 | $4.52 | +113% |
| Q3 2025 | $3.78 | +244% |
| Q2 2025 | $3.04 | +1026% |
| Q1 2025 | $2.76 | +$3.26 |
| Q4 2024 | $2.12 | +$3.11 |
| Q3 2024 | $1.10 | +$2.35 |
SKHY has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SKHY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $59.4B | +257% |
| Q1 2026 | $39.4B | +198% |
| Q4 2025 | $24.6B | +66% |
| Q3 2025 | $18.3B | +39% |
| Q2 2025 | $16.7B | +35% |
| Q1 2025 | $13.2B | +42% |
| Q4 2024 | $14.8B | +75% |
| Q3 2024 | $13.2B | +94% |
SKHY has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 76% | +35 points |
| Q1 2026 | 72% | +29 points |
| Q4 2025 | 58% | +18 points |
| Q3 2025 | 47% | +6.6 points |
| Q2 2025 | 41% | +8.1 points |
| Q1 2025 | 42% | +19 points |
| Q4 2024 | 41% | +38 points |
| Q3 2024 | 40% | +60 points |
SKHY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
SKHY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $41.2B | +1111% |
| Q1 2026 | $13.8B | +619% |
| Q4 2025 | $6.5B | +142% |
| Q3 2025 | $6.8B | +127% |
| Q2 2025 | $3.4B | +26% |
| Q1 2025 | $1.9B | +20% |
| Q4 2024 | $2.7B | +67% |
| Q3 2024 | $3B | +$3.4B |
SKHY has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SKHY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +14.8M shares |
| 1 year | +0.2% | +14.8M shares |
| 3 years | +3.7% | +254M shares |
| 5 years | +3.9% | +268M shares |
| Available history | +4.3% | +294M shares |
SKHY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SKHY hasn't bought back shares in the past year.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over SKHY on leverage, with a lower net debt burden relative to earnings.
SKHY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | 0.0x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.4x | Very low |
| Q3 2024 | 0.6x | Very low |
SKHY has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SKHY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 19.7 | Oversold |
SKHY's weekly RSI is 29 (oversold) and its Stochastic is 20 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SKHY PE vs Technology Sector
SKHY has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has stronger trend alignment. OSCR is above 5 of 5 weekly averages versus SKHY above 0 of 1.
SKHY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $155.4 | 11% below |
SKHY is in a downtrend: it's below all one of its weekly moving averages, and 11% below its 8-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SKHY on returns for 2026, with the stronger performance.
SKHY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $168.0 | $137.7 | -18% |
It's down 18% so far in 2026.